Background: CD101 is a novel echinocandin displaying exceptional chemical stability and a long-acting pharmacokinetics. This compound has being developed for once-weekly IV administration for the treatment of invasive candidiasis and candidemia. We evaluated the activity of CD101 and comparators against 713 invasive fungal isolates collected worldwide during 2015 using CLSI broth microdilution methods.
Introduction
CD101 (formerly SP 3025; Cidara Therapeutics, Inc.) is a novel echinocandin antifungal agent that displays chemical stability in plasma, aqueous solution, and at elevated temperature as well as long-acting pharmacokinetics. CD101 is in development as a onceweekly IV formulation for the treatment of candidemia and other forms of invasive candidiasis (IC; infection of normally sterile body fluids and tissues). Less frequent dosing of this agent may facilitate shorter and cost-effective hospital stays, provide more convenient (eg, outpatient) prophylaxis or maintenance treatment regimens and support outpatient compliance.
Methods
Fungal organisms. A total of 713 non-duplicate fungal isolates prospectively collected during 2015 from 47 medical centers located in North America (228 isolates; 14 sites), Europe (329 isolates; 18 sites), the Asia-Pacific Region (84 isolates; 7 sites) and Latin America (72 isolates; 8 sites) were evaluated (Figure 1) . Isolates selected were from the following sources: bloodstream infections (427 isolates), pneumonia in hospitalized patients (180), intraabdominal infections (14), skin and skin structure infections (17), and 75 were collected from other or non-specified body sites.
Species identification. Yeast isolates were subcultured and screened using CHROMagar Candida (Becton Dickinson, Sparks, Maryland, USA) to ensure purity and to differentiate Candida albicans/Candida dubliniensis, Candida tropicalis and Candida krusei. Isolates suspected to be either C. albicans or C. dubliniensis (green colonies on CHROMagar) were incubated at 45°C. All other yeast isolates were submitted to Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) using the MALDI Biotyper according to the manufacturer's instructions (Bruker Daltonics, Billerica, Massachusetts, USA). Isolates that were not identified by either phenotypic or proteomic methods were identified using sequencing-based methods as previously described.
Antifungal susceptibility testing. All isolates were tested by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) methods outlined in documents M27-A3 and M38-A2. Frozenform panels used RPMI 1640 broth supplemented with MOPS (morpholinepropane sulfonic acid) buffer and 0.2% glucose. MIC/MEC values were determined visually, after 24, 48 or 72 hours of incubation at 35ºC, with MIC defined as the lowest concentration of drug that resulted in ≥50% inhibition of growth relative to the growth control and MEC defined as the lowest concentration resulting in a change in hyphal morphology. CLSI clinical breakpoints were used for the five most common species of Candida (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei).
Epidemiological cutoff values (ECV) were applied when available. Quality control was performed as recommended in CLSI documents M27-A3 and M38-A2 using strains C. krusei ATCC 6258, C. parapsilosis ATCC 22019, Aspergillus flavus ATCC 204304 and A. fumigatus MYA-3626.
Screening for 1,3-β-D-glucan synthase mutations. All isolates of Candida spp. that were either resistant or non-wild-type (NWT; MIC > ECV) to one or more of the echinocandins were characterized for the presence or absence of a mutation in the hot spot (HS) regions of fks1 and fks2 (C. glabrata only) as described previously.
Results
• Among the 713 fungal clinical isolates tested, 589 (82.6%) were Candida spp., 14 (1.9%) C. neoformans var. grubii, 13 (1.8%) A. flavus species complex and 97 (13.6%) were A. fumigatus. The distribution of isolates according to the geographic regions is displayed in Figure 1 .
• CD101 (MIC50/90, 0.03/0.06 μg/mL) inhibited 99.7% of 304 C. albicans isolates at ≤0.12 μg/mL ( Table  1) . This compound displayed similar activity to that of anidulafungin and caspofungin (MIC50/90, 0.015/0.03 and ≤0.008/0.015 μg/mL, respectively; Table 1 ).
• CD101 (MIC50 and MIC90, 0.03 and 0.12 μg/mL) inhibited 119 (98.3%) of the C. glabrata isolates at ≤0.12 μg/mL ( Table 1 ). The activity of this investigational echinocandin was comparable to the activity of anidulafungin (MIC50 and MIC90, 0.06 and 0.12 μg/mL) and caspofungin (MIC50 and MIC90, 0.03 and 0.06 μg/mL) and eight-fold less than the activity of micafungin (MIC50 and MIC90, ≤0.008 and 0.015 μg/mL; Table 1 ).
• All C. parapsilosis isolates were inhibited by CD101 at ≤2 μg/mL, the current CLSI susceptible breakpoint for the approved echinocandins tested against this Candida species ( Table 1) . CD101 (MIC50 and MIC90, 1 and 2 μg/mL) displayed similar activity to that of micafungin (MIC50/90, 1/1 μg/mL) and anidulafungin (MIC50/90, 2/2 μg/mL) and was four-fold less active than caspofungin (MIC50/90, 0.25/0.5 μg/mL).
• C. tropicalis (55 isolates) were considered susceptible to the clinically available echinocandins, and CD101 (MIC50/90, 0.03/0.06 μg/mL) inhibited all isolates at ≤0.12 μg/mL ( Table 1 ).
• CD101 (MIC50 and MIC90, 0.03 and 0.06 μg/mL) was very active against 14 C. krusei and all isolates were inhibited at ≤0.12 μg/mL ( Table 1) . These isolates were susceptible to anidulafungin (MIC50/90, 0.03/0.12 μg/mL), caspofungin (MIC50/90, 0.12/0.25 μg/mL) and micafungin (MIC50/90, 0.06/0.12 μg/mL) according to the CLSI breakpoint criteria.
• The activity of CD101 (MIC50 and MIC90, 0.03 and 0.06 μg/mL; Table 1 ) against C. dubliniensis isolates was comparable to those of anidulafungin (MIC50 and MIC90, 0.03 and 0.06 μg/mL), caspofungin (MIC50 and MIC90, 0.015 and 0.03 μg/mL) and micafungin (MIC50 and MIC90, 0.015 and 0.015 μg/mL).
• Echinocandins, including CD101, displayed limited activity (MIC ≥8 μg/mL) against C. neoformans var. grubii isolates (n=14; Table 1 ).
• Echinocandins displayed good activity against A. fumigatus and CD101 (MEC50 and MEC90, 0.015 and 0.03 μg/mL) activity was similar to that of anidulafungin (MEC50 and MEC90, ≤0.008/0.03 μg/mL), caspofungin (MEC50/90, 0.015/0.03 μg/mL) and micafungin (≤0.008/0.015 μg/mL).
• Echinocandins displayed good activity against A. flavus species complex and CD101 (MEC50 and MEC90, ≤0.008 and 0.03 μg/mL) activity was similar to that of anidulafungin (MEC50 and MEC90, 0.015/0.015 μg/mL), caspofungin (MEC50/90, 0.015/0.03 μg/mL) and micafungin (0.015/0.015 μg/mL).
• Four Candida spp. isolates displayed non-wild-type echinocandin MIC values and were screened for fks mutations ( Table 2) . Three isolates were C. glabrata and only one isolate displaying resistant MIC results for these clinically available echinocandins (according to the current CLSI breakpoints) carried fks1 HS1 alteration (F625S). One C. albicans was resistant to both caspofungin and micafungin (MIC, 1 μg/mL) and displayed an fks1 HS1 alteration S645P.
Conclusions
• The activity of CD101 against common fungal species isolated from invasive infections was comparable to clinically available echinocandins and variations of ±two-fold were noted for different species when CD101 was compared to anidulafungin, caspofungin and micafungin.
• The chemical stability and prolonged half-life of CD101, coupled with the excellent potency and spectrum determined herein, makes CD101 a promising new antifungal agent that may prove to be competitive with currently approved echinocandins for improved prophylactic and treatment efficacy of invasive candidiasis. 
